 |
 |

Vitamins and Hormone Therapy for Coronary Atherosclerosis
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
In Reply: In response to Dr Hathcock, the predefined primary outcome of our trial was coronary angiographic change, with worse ranks assigned to women who died or had an intercurrent MI. We agree that there is no 1-to-1 relationship between clinical outcome and angiographic change, which is why women who died or had an MI were not imputed an equivalent angiographic score, but rather were assigned a rank that was lower than the rank of the worst angiographic score. The nonparametric test we used thus relies on the relative ordering of the outcomes, not their numeric value, and we do feel it is reasonable to rank deaths and MIs lowest.
Hathcock is also concerned about multiple comparisons. The tables show many comparisons, and many more were done that were not reported. The tests for deaths and MIs, as the 2 components of the primary outcome, however, were prespecified at the . . . [Full Text of this Article]
RELATED ARTICLE
Vitamins and Hormone Therapy for Coronary Atherosclerosis
John N. Hathcock
JAMA. 2003;289(8):982.
EXTRACT
| FULL TEXT
|